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Exposure of Treating Physician to Radiation during 
Prostate Brachytherapy Using Iodine-125 Seeds
Dose Measurements on Both Hands with Thermoluminescence Dosimeters
Hans Schiefer1, Friedrich von Toggenburg2, Wolf Seelentag1, Ludwig Plasswilm1, Gerhard Ries1, 
Cornelius Lenggenhager2, Hans-Peter Schmid2, Thomas Leippold2, Ladislav Prikler3, Bernd Krusche4, 
Jakob Roth5, Daniel Engeler2
Background and Purpose: Only sparse reports have been made about radiation exposure of the treating physician during 
prostate seed implantation. Therefore, thermoluminescence dosimeter (TLD) measurements on the index fingers and the backs of 
both hands were conducted.
Material and Methods: Stranded iodine-125 seeds with a mean apparent activity of 27.4 MBq per seed were used. During ap-
plication, the treating physician manipulated the loaded needle with the index fingers, partially under fluoroscopic control. Four 
physicians with varying experience treated 24 patients. The radiation exposure was determined with TLD-100 chips attached to 
the index fingertips and the backs of hands. Radiation exposure was correlated with the physician’s experience.
Results: The average brachytherapy duration by the most experienced physician was 19.2 min (standard deviation σ = 1.2 min; 
novices: 34.8 min [σ = 10.2 min]). The mean activity was 1,703 MBq (σ = 123 MBq), applied with 16.3 needles (σ = 2.5 needles; 
novices: 1,469 MBq [σ = 229 MBq]; 16.8 needles [σ = 2.3 needles]). The exposure of the finger of the “active hand” and the back 
of the hand amounted to 1.31 mSv (σ = 0.54 mSv) and 0.61 mSv (σ = 0.23 mSv), respectively (novices: 2.07 mSv [σ = 0.86 mSv] 
and 1.05 mSv [σ = 0.53 mSv]).
Conclusion: If no other radiation exposure needs to be considered, an experienced physician can perform about 400 applications 
per year without exceeding the limit of 500 mSv/year; for novices, the corresponding figure is about 200.
Key Words: Prostate cancer · Brachytherapy · Iodine-125 seeds · Radiation exposure · TLD
Strahlenther Onkol 2009;185:689–95
DOI 10.1007/s00066-009-1990-z
Strahlenexposition des applizierenden Arztes bei der Brachytherapie mit Iod-125-Seeds. Dosismessungen an beiden 
Händen mit Thermolumineszenzdosimetern 
Hintergrund und Ziel: Zur Strahlenexposition des applizierenden Arztes bei der Brachytherapie mit Iod-125-Seeds, insbesonde-
re an den Fingern, existieren kaum Informationen. Mit TLD (Thermolumineszenzdosimeter) wurden deshalb Dosismessungen an 
den die Nadel führenden Zeigefingern und den Handrücken jeweils beider Hände durchgeführt (Abbildung 2) und mit der Erfahrung 
des Applizierenden korreliert.
Material und Methodik: Es wurden Iod-125-Seedketten mit einer mittleren scheinbaren Aktivität von 27,4 MBq pro Seed ver-
wendet (Tabelle 1). Während der Applikation manipulierte der Arzt die beladenen Nadeln mit den Zeigefingern, teilweise unter 
Durchleuchtung (Abbildung 1). Vier Ärzte mit unterschiedlicher Erfahrung behandelten 24 Patienten. Die Strahlenbelastung wur-
de mit TLD-100-Chips gemessen, welche auf beide Zeigefinger und die Handrücken aufgeklebt wurden (Abbildung 2).
Ergebnisse: Eine Applikation des Arztes mit der größten Erfahrung dauerte durchschnittlich 19,2 min (Standardabweichung 
σ = 1,2 min), wobei er im Mittel 1 703 MBq (σ = 123 MBq) in 16,3 Nadeln (σ = 2,5 Nadeln) verwendete. Ein unerfahrener Operateur 
benötigte für eine Applikation von durchschnittlich 1 469 MBq (σ = 229 MBq) mit 16,8 Nadeln (σ = 2,3 Nadeln) im Mittel 34,8 
min (σ = 10,2 min) (Abbildungen 3 und 4). Die beim erfahrenen Arzt gemessene mittlere Strahlenexposition des stärker belaste-
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Introduction
The standard radiotherapeutic approach to the treatment of 
localized tumors of the prostate has changed dramatically 
over the past 20 years [17]. The reasons are the increase in the 
proportion of low-risk cancers and new treatment techniques 
[26]. Brachytherapy of the prostate with iodine-125 seeds was 
introduced in Switzerland in 2001 and is increasing in impor-
tance. In addition to control of the tumor, preservation of the 
patient’s quality of life is a prime objective of therapy. Fur-
thermore, the risk of cancer induction by the irradiation is 
lower than with external irradiation [19].
At St. Gallen Cantonal Hospital, Switzerland, we use 
brachytherapy to treat patients with low- and moderate-risk 
clinically localized cancer of the prostate [11, 23]. The low-risk 
group includes patients with carcinomas that meet the fol-
lowing criteria: maximum clinical stage T2a, prostate-specific 
antigen (PSA) value ≤ 10 ng/ml, and Gleason Score ≤ 6 [7]. 
The moderate-risk group includes those who meet two of the 
low-risk criteria and have a maximum of one of the following: 
clinical stage T2b, PSA value > 10 to ≤ 20 ng/ml, or Gleason 
Score = 7. The patient’s risk group, however, is of no relevance 
for the topic of this study. Patients who have undergone trans-
urethral resection of the prostate are not eligible for brachy-
therapy. The prostatic volume has to be < 60 cm3 mainly for 
technical reasons. Similar to other groups [15], we character-
ize the success of the application with the dose parameters 
V100 (volume receiving 100% of the prescribed dose), D90 
and D80 (dose received by 90% and 80% of the target volume, 
respectively).
The basic principles of radiation protection are followed 
as far as possible: the manufacturer supplies the seeds in a 
metal magazine that absorbs most of the radiation (shielding). 
The trimming of the seed chains to the planned length and 
the loading of the needles is semiautomatic, using a loading 
station behind a lead glass shield (time, distance, shielding). 
The loaded needles are stored in a metal container at least 1 m 
from the surgical staff until they are used (shielding, distance). 
During application, however, the treating physician massively 
contravenes three golden rules of radiation protection: the 
distance between the finger inserting the needle and the radia-
tion source is < 1 mm at times (no distance), and the seeds are 
manipulated without any protection at all (no shielding). The 
overall duration of manipulation close to the radiation source 
can be markedly longer than 10 min (time).
The dose burden to the patient is well known [10, 24]. A 
number of investigations have also evaluated the radiation 
dose for medical staff and the relatives of patients treated with 
radioactive substances. Cattani et al. [6] showed that the radia-
tion exposure of relatives of brachytherapy patients is well be-
low the legal threshold. Investigations into radiosynoviorthesis 
patients showed that the finger exposure of the staff can exceed 
the annual dose limit of 500 mSv when working at low protec-
tion standard [18]. Other groups studied radiation exposure 
in staff involved in interstitial brachytherapy with gold seeds 
and recommended that optimized radiation protection mea-
sures be applied [20]. Using thermoluminescence dosimeters 
(TLDs), a dose of 0.6 mSv per application was measured on 
the fingertips of the attending physicians involved in treatment 
of cervical carcinoma with implants of 60 mg radium [12].
Effective doses Hp(10) and the equivalent dose Hp(0.07) 
of < 30 and 420 µSv per application were measured using 
film and finger ring dosimeters during brachytherapy with 
 iodine-125 seeds [1]. In contrast, Hp(0.07) values up to 1 mSv 
were measured on the hands [14]. These measurements, how-
ever, can hardly be used as indicators of the dose absorbed 
by the most highly exposed side of the index finger which the 
treating physician uses to guide the needle.
In the present study, measurements of the radiation dose 
using TLD on both index fingers and the backs of the hands of 
physicians performing brachytherapy are reported.
Material and Methods
Patients
Data were collected during application of seeds for prostate 
brachytherapy in 24 consecutive patients at two institutions 
from April 2006 to January 2007. Clinical T-categories were 
T1 and T2 in 18 and six patients, respectively, Gleason Scores 
of 6 and 5 were found in biopsy specimens of 22 and two pa-
tients, respectively. The mean PSA level was 6.5 ng/ml (σ = 3.0 
ng/ml; minimum = 2.1 ng/ml, maximum = 14.0 ng/ml).
Material
Isocord iodine-125 seed chains (Eckert & Ziegler, BEBIG, 
Berlin, Germany) were used for brachytherapy of the pros-
tate. The half-life of the nuclide is 59.4 days. A seed consists of 
a sealed 4.5 mm long titanium rod with an external diameter 
of 0.8 mm surrounding the isotope iodine-125. Under normal 
conditions of use, this prevents escape of the radioactive iso-
tope and rules out any possibility of contamination. The hol-
low needles (18 G) are made of stainless steel with an internal 
diameter of 1.1 mm. There is only negligible shielding of ra-
diation because the needle wall is thinner than 0.1 mm.
ten Fingers betrug 1,31 mSv (σ = 0,54 mSv), jene des Handrückens 0,61 mSv (σ = 0,23 mSv). Die korrespondierenden Werte des 
unerfahrenen Operateurs lagen bei 2,07 mSv (σ = 0,86 mSv) bzw. 1,05 mSv (σ = 0,53 mSv) (Abbildungen 5, 6a und 6b. 
Schlussfolgerung: Ohne Berücksichtigung anderer Strahlenexpositionen kann ein erfahrener Arzt pro Jahr etwa 400, ein uner-
fahrener Arzt etwa 200 Applikationen durchführen, ohne den Dosisgrenzwert von 500 mSv/Jahr zu überschreiten.
Schlüsselwörter: Prostatakarzinom · Brachytherapie · Iod-125-Seeds · Strahlenexposition · TLD
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The ultrasound head used for rectal imaging is mounted on-
to the stepping unit (Brachystepper with Brachystand 6 Ultra, 
Barzell-Whitmore Maroon Bells, Inc. Sarasota, FL, USA) and 
can be gradually advanced longitudinally into the rectum [8]. A 
plastic template with a grid of 5-mm holes is fixed onto the step-
ping unit (B & K Standard, BK Medical, Herlev, Denmark). 
Together with the stepping unit, this template determines the 
coordinate system. The prostate is coupled to the coordinate 
system using two fixation needles [13] (Figure 1). The software 
of the ultrasound device superimposes the template grid on the 
ultrasound image. The Variseed 7 (Varian Medical Systems 
Inc., Palo Alto, CA, USA) program is used to plan the irradia-
tion. A loading station developed by the seed manufacturer is 
used to trim the seed chains and load the needles.
Methods
The application method is described elsewhere [13]. The 
planning target volume (PTV) is defined of the prostate 
plus a margin of 3 mm (laterally), 5 mm (base), and 2 mm 
(apex), respectively. The prescribed dose based on the PTV is 
145 Gy. To determine the optimum seed position, the plan-
ning system takes the following dosimetric constraints into 
account:
PTV:        V100  ≥ 95% of the prescribed dose;
         D90  ≤ 125% of the prescribed dose;
urethra:  D5     ≤ 150% of the prescribed dose;
rectum:   V100 ≤ 0.3 cm
3.
During application, the physician uses the ultrasound image 
(all three planes) and the fluoroscope (longitudinally) for ori-
entation. The staff wear lead aprons and the treating physician 
also a thyroid shield.
The treating physician controls the insertion direction of 
the needle by turning the beveled end of the needle. If this 
is not enough, the physician applies pressure on the needle 
with the side of the finger controlling the needle facing the 
thumb. At this time, the hand is between the template and the 
patient’s perineum, at times therefore in the scatter region of 
the fluoroscope (Figure 1). The distance between the side of 
the index finger and the seeds is therefore markedly less than 
1 mm at such times. Since this procedure relies a great deal on 
“feeling” [16, 22], the treating physician does not wear lead 
gloves. These would impede sensitivity and lengthen the dura-
tion of the application, and in turn increase the exposure to 
radiation [1, 9, 25].
Both the seeds and the fluoroscope contribute to the ra-
diation exposure to the hands. TLD-100 discs (Ø = 4.5 mm; 
thickness = 0.9 mm; manufacturer: Harshaw, now: Thermo 
Scientific Inc., Waltham, MA, USA) sealed in plastic sheeting 
are affixed to the radial index finger sides and on the back of 
both hands to measure the exposure (Figure 2). Three or four 
TLDs are applied per measuring point.
The most experienced physician (about 50 brachythera-
pies within the last 2 years) performed six applications. The 
other three treating physicians (fewer than ten applications 
at the beginning of the exposure measurements) performed a 
total of 18 applications. The doses at the fingertips were mea-
sured for all 24 applications, and on the backs of the hands for 
22. The higher values are used for interpretation.
A PTW-TLDO oven (PTW, Freiburg, Germany) was 
used to anneal the TLDs, and a 5500 Reader (Harshaw) was 
Figure 1. Application of the hollow needles.
Abbildung 1. Applikation der Hohlnadeln.
Figure 2. Position of the TLDs on the index fingers and backs of hands.
Abbildung 2. Position der TLDs an den Zeigefingern und Handrücken.
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used for evaluation. The actual sensitivity of the TLD reader 
system was determined by irradiating ten TLDs from the same 
evaluation batch using a cobalt-60 device. The conversion fac-
tor from cobalt-60 to iodine-125 was taken from the literature 
and verified with phantom measurements.
The degree of radiation exposure measured was corre-
lated with the experience of the treating physician.
Results
Statistics of Applied Seeds
Statistical information on prostate volumes, the seeds applied, 
their activity, the needles, and application times are given in 
Table 1.
Per session, the experienced physician applied a mean of 
1,703 MBq (σ = 123 MBq) in 16.3 needles (σ = 2.5 needles), 
and the novices 1,469 MBq (σ = 229 MBq) in 16.8 needles 
(σ = 2.3 needles). Although the experienced physician ap-
plied a slightly higher activity of Δ = 235 MBq (σ = 260 MBq), 
the overall mean number of needles applied can be assumed 
as identical (Δ = 0.5; σ = 3.4). The mean application time for 
the experienced physician was 19.2 min (σ = 1.2 min; mini-
mum = 17 min, maximum = 20 min). The novices needed 
almost twice as long with a mean of 34.8 min (σ = 10.2 min; 
minimum = 22 min, maximum = 60 min) (Figure 3).
Table 1. Mean, standard deviation (SD), minimum and maximum for 
application parameters.
Tabelle 1. Mittelwert, Standardabweichung (SD), Minimum und Maxi-
mum verschiedener Applikationsparameter.
 Mean SD Minimum Maximum
Prostate volume (cm3) 44.3  11.0  26.8  64.6
Seeds per application (n) 55.5 6.9  40 70
Activity per seed (MBq) 27.4 1.5  23.6 28.8
Activity per application 
(MBq) 1,527.4 231.4 1,124.8 1,947.7
Needles per application (n) 16.7 2.4 12 22
Application time (min) 30.9  11.2 17 60
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Figure 3. Application times for 24 seed implantations of the prostate.
Abbildung 3. Applikationszeiten für 24 Prostataimplantationen.
Figure 4. Correlation between application time and number of 
needles. Black diamonds: datapoints for experienced physician.
Abbildung 4. Zusammenhang zwischen Applikationszeit und Zahl 
der Nadeln. Die Datenpunkte für den erfahrenen Urologen sind mit 
schwarzen Rauten dargestellt.
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There was only a weak correlation between the number 
of needles applied and application time (Figure 4): Pearson’s 
correlation coefficient R was 0.46. 
Dose Measurements
Means of 1.31 mSv (σ = 0.54 mSv) on the fingers and 0.61 mSv 
(σ = 0.23 mSv) on the backs of the hands were found for the 
experienced physician. The respective values for the novices 
were 2.07 mSv (σ = 0.86 mSv) and 1.05 mSv (σ = 0.53 mSv; 
Figure 5). Anglesio et al. [1] reported a 50% lower dose on the 
hands of experienced surgeons, which is in the same order of 
magnitude.
The following plausible assumptions were made with re-
gard to the extent of exposure to radiation:
•    The doses measured on the backs of the hands were pri-
marily attributable to the fluoroscope.
•    The fingers and backs of the hands were subject to similar 
degrees of exposure from the fluoroscope.
The ratio between the doses measured for the fingers and backs 
of hands were determined for 22 appli-
cations. The mean was 2.09 (σ = 0.61), 
and there was no significant difference 
between the experienced physician 
(2.04; σ = 0.35) and the novices (2.11; 
σ = 0.67; p = 1.0). Based on the above as-
sumptions, it can be concluded that the 
fluoroscope accounts for about half of 
the exposure at the fingers.
 Dependencies of the Measured  
Dose
With this limited number of applica-
tions, a mild correlation between the 
finger dose and the number of needles 
applied (R = 0.48) and application time 
was observed (R = 0.60), as shown in 
Figure 6. This is, however, not surpris-
ing, since the duration of the applica-
tions is weakly related to the number of 
needles applied.
However, the finger dose did not 
depend on the number of seeds applied 
(results not presented here, R = 0.08). 
This indicates that the local dose to the 
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Figure 5. Exposure on fingers and backs of hands grouped according to experience of treating 
physician. The bars cover the dose range measured.
Abbildung 5. Dosisbelastung an den Fingern und Handrücken, gruppiert nach der Erfahrung der 
Applizierenden. Die Balken umspannen den gemessenen Dosisbereich.
Figures 6a and 6b. Correlation between finger exposure and number of needles applied (a) and application time (b). Black diamonds: datapoints 
for experienced physician.
Abbildungen 6a und 6b. Abhängigkeit der Fingerdosis von der Zahl der applizierten Nadeln (a) und der Applikationszeit (b). Die Datenpunkte für 
den erfahrenen Urologen sind mit schwarzen Rauten dargestellt.
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finger mainly depends on the seed directly under the area 
where pressure is applied by the finger, and that the remain-
ing seeds play a subordinate role because of the dose-distance 
inverse square law. 
Discussion
Radiation protection legislation in the EU countries stipulates 
a threshold level for the effective dose on the hands of 500 mSv 
per year [2–4]. According to the Austrian radiation protec-
tion legislation the threshold value must not be exceeded by 
the dose averaged over 1 cm2 [4]. The mean annual extremity 
dose in radiation therapy, reported for France, Germany and 
Ireland for the year 2005, is between 2 and 8 mSv. Individual 
doses > 50 mSv are reported [9]. It has to be assumed that the 
maximum skin dose is several times larger [25]. Nevertheless, 
there are very few published data about the dose to the hands 
in manual brachytherapy [9, 25].
In most diagnostic radiology procedures the dose to the 
hands will be fairly homogeneous. During manual seed inser-
tion into the prostate, however, it is obvious that the skin of 
the fingertip leading the needle gets the maximum dose and 
therefore limits the number of applications from the view-
point of radiation protection [5, 9, 25].
The dose to the fingertips can be considerably higher than 
the dose measured with a ring dosimeter worn at the usual 
position [25]. It is composed of two dose contributions with 
varying weights, originating from the seeds and the fluoros-
copy. Consequently, it is difficult to deduce the dose to the 
fingertips from ring dosimeter measurements, as proposed by 
Vanhavere et al. [25]. These considerations have motivated 
the measurements presented in this study.
The TLDs used in our study covered an area of about 
1 cm2 and were applied on the regions of highest exposure. 
We were therefore able to assess whether the threshold value 
mentioned in [4] was complied with.
Our measurements of exposure of the side of the finger in-
troducing the needle showed that the annual threshold value 
will usually not be exceeded. An experienced physician with 
a mean application time of about 20 min can conduct almost 
400 brachytherapy sessions without exceeding the threshold 
value. Physicians with little experience (less than ten appli-
cations, mean application time of about 35 min) are exposed 
to almost twice as much radiation, which agrees with mea-
surements made by other research groups [1]. This means 
that novices could perform about 200 applications per year – 
not taking into account that by the end of the year they would 
no longer have to be considered as novices (the “experienced” 
physician in the present study had conducted about 50 brachy-
therapy applications). These estimates do not, however, take 
radiation exposures from other sources into account.
Palladium-103 seeds are also used for prostatic brachy-
therapy [17]. A simple estimate based on a comparable ap-
plication procedure indicates that palladium seeds are likely 
to expose the finger sides about 50% higher than iodine-125 
seeds.
The fluoroscope accounts for about half of the radiation 
exposure of the fingers. The same degree of exposure, how-
ever, can be expected for a much larger area of the body. The 
contribution of fluoroscopy therefore markedly exceeds that 
of the seeds [21]. Careful attention should be paid to protec-
tion of the whole body, and especially the thyroid, when per-
forming brachytherapy of the prostate.
Conclusion
Unless other radiologic procedures contribute considerably 
to the exposure of the fingers, some 200–400 manual prostate 
seed implants may be performed by a single individual with-
out exceeding critical values.
For doses to the trunk the contribution from the seeds is 
negligible. Standard radiation protection measures for com-
parable radiologic procedures should be applied.
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